Literature DB >> 34226586

miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells.

Chisaho Torii1,2,3, Nako Maishi1,2,4, Taisuke Kawamoto1, Masahiro Morimoto2,4,5, Kosuke Akiyama1, Yusuke Yoshioka6, Takashi Minami7, Takuya Tsumita4, Mohammad Towfik Alam1,2,4, Takahiro Ochiya6, Yasuhiro Hida8, Kyoko Hida9,10,11.   

Abstract

Tumor endothelial cells (TECs) reportedly exhibit altered phenotypes. We have demonstrated that TECs acquire drug resistance with the upregulation of P-glycoprotein (P-gp, ABCB1), contrary to traditional assumptions. Furthermore, P-gp expression was higher in TECs of highly metastatic tumors than in those of low metastatic tumors. However, the detailed mechanism of differential P-gp expression in TECs remains unclear. miRNA was identified in highly metastatic tumor extracellular vesicles (EVs) and the roles of miRNA in endothelial cell resistance were analyzed in vitro and in vivo. In the present study, we found that treatment of highly metastatic tumor-conditioned medium induced resistance to 5-fluorouracil (5-FU) with interleukin-6 (IL-6) upregulation in endothelial cells (ECs). Among the soluble factors secreted from highly metastatic tumors, we focused on EVs and determined that miR-1246 was contained at a higher level in highly metastatic tumor EVs than in low metastatic tumor EVs. Furthermore, miR-1246 was transported via the EVs into ECs and induced IL-6 expression. Upregulated IL-6 induced resistance to 5-FU with STAT3 and Akt activation in ECs in an autocrine manner. These results suggested that highly metastatic tumors induce drug resistance in ECs by transporting miR-1246 through EVs.

Entities:  

Year:  2021        PMID: 34226586     DOI: 10.1038/s41598-021-92879-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  51 in total

Review 1.  Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results.

Authors:  R S Kerbel
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

Review 2.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

Authors:  Rakesh K Jain; Dan G Duda; Jeffrey W Clark; Jay S Loeffler
Journal:  Nat Clin Pract Oncol       Date:  2006-01

Review 3.  Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.

Authors:  Brian I Rini
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

4.  Repression of Human Hepatocellular Carcinoma Growth by Regulating Met/EGFR/VEGFR-Akt/NF-κB Pathways with Theanine and Its Derivative, (R)-2-(6,8-Dibromo-2-oxo-2H-chromene-3-carboxamido)-5-(ethylamino)-5-oxopentanoic Ethyl Ester (DTBrC).

Authors:  Guoying Zhang; Zheng Li; Xiaochun Wan; Ying Zhang; Rongqin Zhu; Zhenzhen Liu; Dexin Ji; Huarong Zhang; Fei Wu; Huihui Tian; Kun Liu; Benhao Wu
Journal:  J Agric Food Chem       Date:  2016-09-09       Impact factor: 5.279

Review 5.  Inhibition of angiogenesis in the treatment of non-small cell lung cancer.

Authors:  Vicki L Keedy; Alan B Sandler
Journal:  Cancer Sci       Date:  2007-09-24       Impact factor: 6.716

Review 6.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

Review 7.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

8.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

9.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

10.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors:  David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

View more
  5 in total

Review 1.  A New Antitumor Direction: Tumor-Specific Endothelial Cells.

Authors:  Jing Liang; Shouqi Wang; Guowei Zhang; Baoyu He; Qingli Bie; Bin Zhang
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

2.  Identification of Two Exosomal miRNAs in Circulating Blood of Cancer Patients by Using Integrative Transcriptome and Network Analysis.

Authors:  Andrés Rincón-Riveros; Josefa Antonia Rodríguez; Victoria E Villegas; Liliana López-Kleine
Journal:  Noncoding RNA       Date:  2022-05-12

3.  Exosomal microRNAs synergistically trigger stromal fibroblasts in breast cancer.

Authors:  Iolanda Scognamiglio; Lorenza Cocca; Ilaria Puoti; Francesco Palma; Francesco Ingenito; Cristina Quintavalle; Alessandra Affinito; Giuseppina Roscigno; Silvia Nuzzo; Rosario Vincenzo Chianese; Stefania Belli; Guglielmo Thomas; Timo Schomann; Alan Chan; Maria Patrizia Stoppelli; Gerolama Condorelli
Journal:  Mol Ther Nucleic Acids       Date:  2022-02-22       Impact factor: 10.183

4.  Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.

Authors:  Lauretta Levati; Cristian Bassi; Simona Mastroeni; Laura Lupini; Gian Carlo Antonini Cappellini; Laura Bonmassar; Ester Alvino; Simona Caporali; Pedro Miguel Lacal; Maria Grazia Narducci; Ivan Molineris; Federica De Galitiis; Massimo Negrini; Giandomenico Russo; Stefania D'Atri
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

Review 5.  A Review on the Role of miR-1246 in the Pathoetiology of Different Cancers.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Mohammad Samadian
Journal:  Front Mol Biosci       Date:  2022-01-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.